Company / Interest Expense
AMICUS THERAPEUTICS, INC. Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$50.1M
FY2023
5-year range
$32.5M / $50.1M
FY2019-FY2023
Trend
+35.1%
vs FY2022
Sector context
#12 of 44
Health Care
What the data says
At $50M, AMICUS THERAPEUTICS, INC.'s interest expense ranks #33 of 44 in the Health Care sector. Interest Expense has increased for 4 consecutive years, from $19M in FY2019 to $50M in FY2023.
Based on SEC 10-K filings.
$50M in FY2023 with a 5-year CAGR of +17.5%.
Increased from $32M to $50M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +30.8%
- 5-Year CAGR
- +17.5%
- 10-Year CAGR
- -
Sector benchmark
#33 of 44 in Health CareTop 73% of 44This company $50.1M Sector average $291.0M
▼
-82.8% below sector average
Key checks
Key Insights
- AMICUS THERAPEUTICS, INC.'s interest expense has grown for 4 consecutive years.
- 5-year CAGR of +17.5%, indicating consistent growth.
- In FY2023, interest expense increased 35.1% year-over-year.
- Ranks #12 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.19 (distress zone, below 1.8 threshold)
- Negative profit margin: -10.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $50.1M | +35.1% |
| FY2022 | $37.1M | +14.3% |
| FY2021 | $32.5M | +44.8% |
| FY2020 | $22.4M | +18.8% |
| FY2019 | $18.9M | -15.8% |
| FY2018 | $22.4M | +29.9% |
| FY2017 | $17.2M | +219.4% |
| FY2016 | $5.4M | +242.1% |
As of FY2023 · SEC 10-K · Updated Feb 28, 2026